Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Blood (2016) 128 (22): 4263.

https://doi.org/10.1182/blood.V128.22.4263.4263

Published: 2016

Journal Articles

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Arjun Datt Law, MBBS, MDDM, Mahadeo A. Sukhai, BSc, MSc, PhD, Mariam Thomas, PhD, Andrea Arruda, MSc., Narmin Ibrahimova, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Hassan Sibai, MD, Karen W.L. Yee, MD, Dwayne L. Barber, PhD, Tracy L. Stockley, PhD, Suzanne Kamel-Reid, PhD DABMG, FACMG, Andre C. Schuh, MD FRCPC

Blood (2016) 128 (22): 2886.

https://doi.org/10.1182/blood.V128.22.2886.2886

Published: 2016

Journal Articles

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD PhD, Isabelle Bence-Bruckler, MD FRCPC, Donna L. Forrest, MD, Mary Lynn Savoie, MD, Stephen Couban, MD, Lambert Busque, MD PhD FRCPC, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Elena Liew, MD, Anargyros Xenocostas, MD, Kristjan Paulson, MD FRCPC, Suzanne Kamel-Reid, PhD DABMG, FACMG, Jeff H. Lipton, MD PhD, Brian Leber, MD

Blood (2016) 128 (22): 1922.

https://doi.org/10.1182/blood.V128.22.1922.1922

Published: 2016

Journal Articles

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

Blood (2015) 126 (23): 3848.

https://doi.org/10.1182/blood.V126.23.3848.3848

Published: 2015

Journal Articles

Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis

Uday Deotare, MD DM, Marwan Shaheen, MD, Joseph M. Brandwein, MD FRCPC, Bethany Gill, BSc, MMath, Suzanne Kamel-Reid, PhD DABMG, FACMG, Karen W.L. Yee, MDFRCPC, Anna Rydlewski, MD, Andrzej Lutynski, MD, Amr Rostom, MDCFPC, Aaron D Schimmer, MDPhD, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS,MD, Andre C Schuh, MD FRCPC

Blood (2014) 124 (21): 3693.

https://doi.org/10.1182/blood.V124.21.3693.3693

Published: 2014

Journal Articles

Mixed Fields on RHD Typing As an Indicator of Malignancy-Associated Loss of Heterozygosity on Chromosome 1p in Myeloid Neoplasm

Signy Chow, MD FRCPC, Jacob M Pendergrast, MD FRCPC, Gorka Ochoa-Garay, Vikas Gupta, MD FRCP, FRCPath, Muhammad Ejaz Munir, MBBS, FRCS, Cuihong Wei, PhD FCCMG, Kenneth J Craddock, MD FRCPC, Suzanne Kamel-Reid, PhD DABMG, FACMG, Christine Cserti-Gazdewich, MD FRCPC

Blood (2014) 124 (21): 5105.

https://doi.org/10.1182/blood.V124.21.5105.5105

Published: 2014

NARROW

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis

Mixed Fields on RHD Typing As an Indicator of Malignancy-Associated Loss of Heterozygosity on Chromosome 1p in Myeloid Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis

Mixed Fields on RHD Typing As an Indicator of Malignancy-Associated Loss of Heterozygosity on Chromosome 1p in Myeloid Neoplasm

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only